BTG (LSE: BTG) has expanded its pulmonary embolism (PE) business by acquiring Novate Medical Ltd., a startup focused on the prevention of PE in patients at high risk of venous thromboembolic events.
Founded in 2006, Novate (Galway, Ireland) develops inferior vena cava (IVC) filters to reduce the likelihood of pulmonary embolism in high-risk clinical situations. Its Sentry device is the first bioconvertible IVC filter and recently won 510(k) clearance from the FDA. Sentry’s 12-month clinical trial data demonstrated no new symptomatic PE and no evidence of device migration, tilt, fracture, perforation or embolization, complications that have been associated with some other IVC filters. The unique bioconversion feature eliminates the need for an additional interventional procedure to retrieve the device.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.